The warrants of series TO 4 were issued in connection with the rights issue announced on 20 February 2024, with a subscription period that ended on 17 April 2024. Each warrant entitles the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.15. The exercise period for the warrants runs from 17 November 2025 to 1 December 2025.

The subscription price of SEK 0.15 was determined before the issuance of new shares in the separate rights issue carried out in November 2024. Based on the current share price, the warrants are considered to be out of the money, meaning that the subscription price, taking into account the effect of a customary recalculation exceeds the market price of the Company's share.

For more information, please visit www.spermosens.com.

For further information, please contact:
Tore Duvold, CEO
Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science-driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision in evaluations by measuring sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatment strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.